Ndwm LLC Makes New Investment in iShares Biotechnology ETF $IBB

Ndwm LLC purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 6,931 shares of the financial services provider’s stock, valued at approximately $1,459,000. iShares Biotechnology ETF comprises 0.8% of Ndwm LLC’s investment portfolio, making the stock its 23rd largest position.

Several other hedge funds and other institutional investors also recently bought and sold shares of IBB. Bank of America Corp DE raised its position in shares of iShares Biotechnology ETF by 10.8% during the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after buying an additional 707,343 shares during the last quarter. Royal Bank of Canada grew its position in iShares Biotechnology ETF by 1.0% during the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after buying an additional 7,434 shares in the last quarter. Jefferies Financial Group Inc. grew its position in iShares Biotechnology ETF by 38.1% during the third quarter. Jefferies Financial Group Inc. now owns 417,500 shares of the financial services provider’s stock worth $87,896,000 after buying an additional 115,194 shares in the last quarter. Commonwealth Equity Services LLC grew its position in iShares Biotechnology ETF by 1.3% during the third quarter. Commonwealth Equity Services LLC now owns 139,653 shares of the financial services provider’s stock worth $29,401,000 after buying an additional 1,819 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in iShares Biotechnology ETF by 9.4% during the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock worth $21,702,000 after buying an additional 10,994 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $218.14 on Thursday. iShares Biotechnology ETF has a 12-month low of $159.68 and a 12-month high of $222.29. The stock’s 50-day moving average price is $208.98 and its 200 day moving average price is $186.54.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were given a $0.0112 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.0%. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

See Also

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.